Testing Akkermansia gut bacteria supplement for overweight and obesity
Compares an Akkermansia supplement with a placebo in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: Gut Microbiota-Based Clinical Study of Akkermansia Supplementation for Overweight and Obesity
Key facts
- Where
- Nanchang, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07898267, who can take part
Where in China
- No. 1, Minde Road, Donghu District, Nanchang University Second Affiliated HospitalNanchang, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Nanchang University
- Trial code
- NCT07898267
- Record updated
- 5 November 2026
- Original description
Overweight and obesity are common metabolic disorders associated with increased risks of diabetes, cardiovascular disease, and other health problems. The gut microbiota plays an important role in regulating metabolism, inflammation, and intestinal health. Akkermansia, a beneficial gut bacterium, has been associated with metabolic health and may have potential benefits for weight management.Read full original descriptionShow less
Gut Microbiota-Based Clinical Study of Akkermansia Supplementation for Overweight and Obesity
Overweight and obesity are common metabolic disorders associated with increased risks of diabetes, cardiovascular disease, and other health problems. The gut microbiota plays an important role in regulating metabolism, inflammation, and intestinal health. Akkermansia, a beneficial gut bacterium, has been associated with metabolic health and may have potential benefits for weight management.
This study aims to investigate the relationship between gut microbiota characteristics and overweight or obesity and to evaluate the efficacy and safety of Akkermansia supplementation in individuals with overweight or obesity.
The study consists of two stages. The first stage is an observational study comparing gut microbiota characteristics between healthy individuals and individuals with overweight or obesity. The second stage is a randomized, double-blind, placebo-controlled clinical trial in which eligible participants with overweight or obesity will receive either Akkermansia supplementation or placebo once daily for 12 weeks, followed by follow-up through Week 24.
The study will evaluate changes in body weight, metabolic health, gut microbiota characteristics, related metabolites, and safety outcomes. The findings may provide clinical evidence regarding the potential use of Akkermansia supplementation for the management of overweight and obesity.
Inclusion: Healthy Controls:; Aged 18-60 years, any sex; BMI between 18.5 and 24.9 kg/m²; Body weight change <5% within the past 3 months; No obesity-related metabolic diseases, including type 2 diabetes mellitus, impaired glucose tolerance, hypertension, dyslipidemia, or nonalcoholic fatty liver disease; No use of antibiotics, probiotics, prebiotics, synbiotics, postbiotics, weight-loss medications, glucocorticoids, or immunosuppressive agents within the past 3 months; No gastrointestinal diseases that may significantly affect gut microbiota; No severe diseases involving the cardiovascular, cerebrovascular, hepatic, renal, hematological, or endocrine systems, and no history of malignant tumors; Not pregnant, lactating, or planning pregnancy; Willing to participate voluntarily, provide fecal and blood samples and clinical data, and sign written informed consent; Overweight/Obese Participants:; Aged 18-60 years, any sex; BMI between 25.0 and 34.9 kg/m²; Body weight change <5% within the past 3 months; Willing to maintain relatively stable dietary habits, physical activity, and daily routines during the study period; Able to complete the 12-week intervention and 24-week follow-up; Willing to provide fecal and blood samples and clinical data; Willing to participate voluntarily and sign written informed consent.
Exclusion: Use of weight-loss medications within the past 3 months, including GLP-1 receptor agonists, orlistat, or metformin used for weight management; Previous bariatric surgery or planned bariatric surgery during the study period; Type 1 diabetes mellitus or type 2 diabetes mellitus requiring insulin therapy; Uncontrolled hypertension, severe cardiovascular or cerebrovascular diseases, severe hepatic or renal dysfunction, malignant tumors, immunodeficiency, or active infections; Gastrointestinal diseases that may significantly affect gut microbiota, including inflammatory bowel disease, short bowel syndrome, chronic diarrhea, severe constipation, or other clinically significant gastrointestinal disorders; Known allergy to any component of the study products; Any condition considered unsuitable for participation by the investigator; Use of antibiotics, probiotics, prebiotics, synbiotics, postbiotics, or other microbiota-modulating products within the past 3 months; Participation in commercial weight-loss programs or intensive lifestyle interventions within the past 3 months; Pregnancy, lactation, or planning to become pregnant during the study; Participation in other clinical studies that may affect study outcomes; For participants entering the second-phase randomized controlled trial, high baseline Akkermansia abundance (Akkermansia abundance ≥1.5%) identified by gut microbiota testing.
This study includes healthy controls and participants with overweight or obesity. Eligibility criteria are as follows:.